| 1.2 -0.075 (-5.88%) | 03-21 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Berkeley Lights, Inc. (BLI) is a digital cell biology firm dedicated to empowering and expediting the advancement and market introduction of biotherapeutic and other cell-based products. The company provides a unified technology platform, which encompasses proprietary consumables such as OptoSelect chips and specialized reagent kits, sophisticated automation systems, and purpose-built application and workflow software. BLI extends its services to clients across North America, the Asia Pacific region, and Europe. Founded in 2011, its corporate headquarters are located in Emeryville, California.
Tue, 21 Mar 2023
Berkeley Lights Completes Acquisition of IsoPlexis Forming PhenomeX, the Functional Cell Biology Company - PR Newswire
Fri, 13 Jan 2023
Berkeley Lights Inc (BLI) Share Price Today | Berkeley Lights Inc (BLI) Live NSE/BSE - Value Research
Mon, 09 Jan 2023
Berkeley Lights Launches Beacon Select™, A New Optofluidic System For Cell Line Development - BioSpace
Wed, 21 Dec 2022
Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology Company - GlobeNewswire
Mon, 25 Jul 2022
Berkeley Lights Announces Mehul Joshi as New Chief Financial Officer - PR Newswire
Thu, 10 Mar 2022
Berkeley Lights Announces Appointment of Dr. Siddhartha Kadia as Chief Executive Officer - SynBioBeta
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|